Particle Sciences Expands Controlled Substance Capabilities with Approval of DEA Schedule I Registration
CLEVELAND, Ohio, May 29, 2019 - (ACN Newswire) - Particle Sciences, a Lubrizol LifeSciences company and pharmaceutical contract development and manufacturing organization (CDMO), has broadened its Drug Enforcement Administration (DEA) registration to become an authorized manufacturer of Schedule I substances. The expanded registration was granted following inspection by the DEA and will allow Particle Sciences to carry out analytical testing, development and manufacturing of cannabis-derived materials to be used in pharmaceutical applications for medically justified, legal uses in the United States.
Particle Sciences already has infrastructure in place to develop and manufacture Schedule II - V controlled drug products at its facility in Bethlehem, PA, and has worked on a number of projects in the past ranging from a novel nasal delivery system for diazepam to long-acting buprenorphine dosage forms. Under its new Schedule I registration, the company will build further on this infrastructure and open a new area of development for customers looking to take products through the traditional clinical trial and approval process.
Robert Lee, president of Particle Sciences states, "Particle Sciences has built a solid reputation and specialized expertise in controlled substances as a result of our team's work in complex formulations with substances in Schedules II - V." Lee continues, "A high level of ethical standards and water-tight controls/processes including accurate documentation are essential to carry out controlled substances work and these are already firmly ingrained in our day-to-day operations."
In 2018, the U.S. Food and Drug Administration (FDA) approved its first cannabis-derived drug, Epidiolex, for the treatment of seizures associated with two rare and severe forms of epilepsy. It has since announced a series of significant steps to develop a regulatory pathway for cannabis-derived products, including the formation of a high-level internal agency working group.
Barbara Morgan, general manager of Particle Sciences comments "The Schedule I registration will open up opportunities for us to work with clients with appropriate sources of controlled substances to further investigate the therapeutic value and effects of these compounds and help shape this emerging area of medicine."
The expanded registration is the latest step in Particle Sciences' broadening of its manufacturing capabilities as part of a wider investment by Lubrizol LifeSciences. The company recently opened a new commercial facility to accommodate production of complex sterile and non-sterile finished drugs and appointed new vice president of operations, Karen Bossert.
For further information, please visit: www.particlesciences.com
About Particle Sciences
Particle Sciences, a Lubrizol LifeSciences company, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA and DEA registered. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2018 were $6.8 billion. For more information, visit Lubrizol.com.
+44 (0)191 222 1242
Particle Sciences: http://hugin.info/143680/R/2245232/886825.jpg
Particle Sciences 2: http://hugin.info/143680/R/2245232/886826.jpg
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Press Release
More Latest Release >>
MHI Again Receives EcoVadis Silver Rating for Overall Sustainability
Oct 20, 2020 15:54 JST
Vodafone and NEC Start Trialing Open RAN Technology
Oct 20, 2020 11:09 JST
Mitsubishi Shipbuilding Receives Approval in Principle for LNG Fuel Gas Supply System from Bureau Veritas
Oct 19, 2020 19:07 JST
Supercomputer Fugaku Wins the "Minister of Internal Affairs and Communications Award" at CEATEC 2020 ONLINE
Oct 19, 2020 18:49 JST
Toyota's GR Yaris Makes Its Dynamic Debut at the Goodwood Speedweek
Oct 19, 2020 18:41 JST
Fujitsu Commences Full-Scale Operation of HOKUSAI - SailingShip, RIKEN's New Data Science Infrastructure
Oct 19, 2020 10:39 JST
New ECLIPSE CROSS Reveals Radical New Styling and Expands Plug-In Hybrid Option
Oct 19, 2020 09:45 JST
Honda Announces Completion of the Tender Offer for Shares in Keihin, Showa and Nissin
Oct 16, 2020 17:16 JST
Showa Denko Markets PNVA(TM) 'GE191 Series' for Use as Binder to Form Heat-resisting Ceramic Layer in Separators for LIBs
Oct 16, 2020 16:00 JST
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Oct 16, 2020 13:44 JST
Fujitsu Verifies Effectiveness of Private 5G in Manufacturing Sites in Collaboration with Microsoft Japan
Oct 16, 2020 11:33 JST
Hitachi Acquired Additional Shares to Hold Majority of Shares of Yungtay, Elevator Company Based in Taiwan
Oct 15, 2020 17:41 JST
Mitsubishi Power Signs MOU with Indonesia's PLN Group and Bandung Institute of Technology (ITB) on Joint Policy Proposal to Promote Biomass Co-firing at Thermal Power Plants in Indonesia
Oct 15, 2020 12:06 JST
Hitachi ABB Power Grids Wins $6.6 Million Projects to Digitalize High-Speed Rail in the UK
Oct 14, 2020 17:48 JST
MHI Group Undertakes Investment in HydrogenPro of Norway, Leading Producer of Advanced Electrolyzers
Oct 14, 2020 15:33 JST
Toyota: Launch of a Preparatory Committee for "Japan Hydrogen Association (JH2A)"
Oct 14, 2020 14:06 JST
Fujitsu Accelerates Digital Transformation at Mizuho Bank Branches with Innovative Tablet Solution
Oct 14, 2020 12:58 JST
Fujitsu and PeptiDream Achieve Milestone in Joint Research for Peptide Drug Candidates with High-Speed, High-Precision Exploration Technology
Oct 13, 2020 17:04 JST
Fujitsu Commences Joint Research with World-Leading Institutions for Innovations in Quantum Computing
Oct 13, 2020 16:41 JST
Hitachi ABB Power Grids and Tensio TN AS to deliver Norway's First Fully Digital, Eco-efficient Substation
Oct 13, 2020 16:25 JST